x

Posted 03 February, 2023

CODEXIS, INC. appointed new CEO

CEO Change detected for ticker Nasdaq:CDXS in a 8-K filed on 03 February, 2023.


  In connection with Mr. Taylor ceasing to serve as Chief Financial Officer, Mr. Taylor and the Company entered into a Transition and Separation Agreement, dated as of February 3, 2023 (the "Transition and Separation Agreement"). Pursuant to the Transition and Separation Agreement, Mr. Taylor will provide transition services and provide advisory services to the Company's Chief Executive Officer on an as-needed basis until March 6, 2023.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of CODEXIS, INC.
Health Care/Life Sciences • Biotechnology
Codexis, Inc. is an enzyme engineering company, which engages in the development and sale of therapeutics. It operates through the Performance Enzymes and Novel Biotherapeutics segments. The Performance Enzymes segment commercializes CodeEvolver protein engineering technology platform and products in the pharmaceuticals market. The Novel Biotherapeutics segment targets new opportunities to discover and improve biotherapeutic drug candidates. Its products include screening kits and Codex HiFi Hot Start DNA Polymerase. The company was founded in January 2002 and is headquartered in Redwood City, CA.
Market Cap
$296M
View Company Details
Relevant filing section
Item 5.02 
Departure of Directors or Certain officers; Election of Directors; Appointment of Certain Officers; Compensation Arrangement of Certain Officers. 


As reported in the Current Report on Form 8-K filed by Codexis, Inc. (the "Company" or "Codexis") on January 23, 2023, Ross Taylor ceased to serve as the Company's Chief Financial Officer and principal financial and accounting officer effective as of the date thereof. 

In connection with Mr. Taylor ceasing to serve as Chief Financial Officer, Mr. Taylor and the Company entered into a Transition and Separation Agreement, dated as of February 3, 2023 (the "Transition and Separation Agreement"). Pursuant to the Transition and Separation Agreement, Mr. Taylor will provide transition services and provide advisory services to the Company's Chief Executive Officer on an as-needed basis until March 6, 2023. During this period, Mr. Taylor shall continue to be paid his base salary, continue to vest into outstanding equity awards and be eligible for employee benefits at the same rate and to the same extent as he was paid and eligible immediately prior to the appointment of our new Chief Financial Officer. In addition, under the Transition and Separation Agreement, in exchange for continuing to serve the Company through March 6, 2023 (or such earlier date as the Company determines to terminate Mr. Taylor's employment for other than cause) and Mr. Taylor's timely delivery of a general release of claims against the Company and its affiliates after his termination of employment, the Company will pay Mr. Taylor as severance 12 months of Mr. Taylor's base salary and, to the extent not previously paid, 85% of Mr. Taylor's target bonus for fiscal year 2022, and will, at its cost, provide Mr. Taylor and his covered dependents with up to 12 months of continued healthcare coverage. Any equity awards that are unvested as of the date Mr. Tayler terminates employment will thereupon be forfeited. 

The foregoing summary of the material terms of the Transition and Separation Agreement is qualified in its entirety by the complete terms of the agreement, which will be filed as an exhibit to Codexis's Quarterly Report on Form 10-Q for the quarter ending March 31, 2023.